Latest news with #LEQSELVI
Business Standard
5 days ago
- Business
- Business Standard
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp
Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S. The drug is indicated for the treatment of alopecia areata a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The pharmaceutical company announced LEQSELVI after entering into a settlement and license agreement with Incyte Corporation. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to patents related to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S. Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. The scrip had advanced 2.71% to end at Rs 1727.70 on the BSE today.
Business Upturn
5 days ago
- Business
- Business Upturn
Top stocks in focus on July 15; Tata Technologies, HCL Tech, RVNL, AstraZeneca Pharma, RailTel and more
By Aman Shukla Published on July 15, 2025, 08:10 IST Indian markets extended their losing streak for the fourth day on Monday. he Nifty 50 slipped 67.55 points to close at 25,082.30, while the Sensex fell 247.01 points to end at 82,253.46. Here's a look at notable stocks in focus today: Stocks to Watch – July 15, 2025 RVNL – Received ₹447 crore order from Delhi Metro for Phase-IV viaduct construction. Best Agrolife – CFO highlights patent wins and branded business growth to aid margins. Sun Pharma – Launched LEQSELVI in the U.S. for treating severe alopecia areata. AstraZeneca Pharma – Received CDSCO approval to market Durvalumab for additional use in India. Tara Chand Infra – Won ₹81.51 crore consignment and handling contract from SAIL. Kranti Industries – Cleared to begin commercial production of gearbox housings for Bonfiglioli. Aarvi Encon – Received a new work order from a leading Indian infrastructure company. Yatharth Hospital – Opened a new facility in Model Town, Delhi on July 14. GG Automotive – Q1 net profit rose to ₹2.6 crore; revenue at ₹28 crore vs ₹25.32 crore YoY. Unicommerce – Partnered with Sennheiser to improve online sales and reduce cart abandonment. RailTel – Received ₹264.07 crore order from East Central Railway for Kavach deployment. Fischer Medical Ventures – Collaborating with Indonesia's Jember on AI-based X-ray systems for TB care. Namo eWaste – Launched lithium-ion battery recycling plant in Nashik, Maharashtra. Den Networks – Q1 profit at ₹53.6 crore vs ₹43.3 crore; revenue dipped slightly YoY. Rallis India – Q1 profit surged to ₹95 crore; revenue up to ₹960 crore vs ₹783 crore YoY. Power Mech Projects – Bagged two new orders worth over ₹550 crore from SJVN and Jhabua Power. Deepak Fertilizers – Signed regasification agreement with Petronet LNG. Sambhav Steel – Reported 47% YoY growth in value-added product volumes to 79,717 tonnes. HCL Tech – Revenue and EBIT largely in line with expectations. Tata Technologies – Posted higher-than-expected Q1 profit and revenue. Brigade Enterprises – To raise up to ₹1,500 crore via private placement of NCDs. Bandhan Bank – Appointed Biju E Punnachalil as Chief Risk Officer for a 3-year term. Karnataka Bank – Raghavendra S Bhat named new MD & CEO, effective July 16. KEC International – Record date set as July 25 for ₹5.50 per share final dividend. Fortis Healthcare – Record date of July 25 for ₹1 per share final dividend. Hawkins Cookers – Set July 30 as record date for dividend payment. BPCL – Appointed Subhankar Sen as Director (Marketing). Nilkamal – Signed agreements to acquire healthcare furniture business from Imedfurns. ONGC – Named Om Prakash Sinha as Director (Exploration). Dhampur Sugar Mills – Issued commercial papers worth ₹100 crore. MTNL – CMD charge for Robert J Ravi extended by another three months. Valor Estate – Appointed Rahul Pandit as CEO and Ajit Jain as CFO at Advent Hotels. Oberoi Realty – ₹919 crore resolution plan for Hotel Horizon approved. LIC – Appointed R Doraiswamy as CEO & Managing Director. JP Power – Circuit filter revised from 20% to 10%. Raymond Realty, Globe Civil – Circuit filters changed from 5% to 20%. Aditya Birla Real Estate – Goes ex-dividend today; ₹2 per share. NELCO – Posted YoY drop in profit to ₹1.8 crore vs ₹4.56 crore; revenue steady. Tejas Networks – Reported net loss of ₹190 crore; revenue dropped sharply YoY. Shiva Mills – Long-term bank rating downgraded to CARE BBB; Stable. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash AstraZeneca PharmaHCL TechRailTelRVNLtata technologies Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Mint
5 days ago
- Business
- Mint
Stocks to watch: HCL Tech, Tata Tech, Rallis India, HDFC Life among shares in focus today amid Trump's tariff news
Shares of HDFC Life Insurance, HDB Financial, ICICI Lombard, Just Dial will remain in focus as companies will declare Q1 results today. HCL Technologies posted a 10% year-on-year decline in its consolidated net profit for the first quarter of FY26, reporting ₹ 3,843 crore compared to ₹ 4,257 crore in the same period last year. For the June quarter, Tata Technologies posted a net profit of ₹ 170 crore, marking a 10% decline from ₹ 189 crore reported in the March quarter. The state-owned company announced that it has secured a ₹ 264 crore (including taxes) work order from East Central Railway for deploying the Kavach system, an indigenously developed Train Collision Avoidance System (TCAS). Rallis India posted a net profit of ₹ 95 crore for the quarter ended June, marking a 98% year-on-year increase. The state-run company announced that it has been awarded a Letter of Award (LOA) by the Delhi Metro Rail Corporation Limited (DMRC) for a project under the Delhi MRTS Phase-IV initiative. Sun Pharma has signed a settlement and licensing agreement with Incyte Corporation to resolve litigation over LEQSELVI (deuruxolitinib). Following this agreement, the company has announced the launch of LEQSELVI in the U.S., where it is approved for treating adults with severe alopecia areata. The company's Board of Directors is scheduled to meet on July 17 to discuss raising funds by issuing equity shares or other securities, either through a rights issue or any other approved method. The company posted a consolidated net loss of ₹ 193.9 crore in the first quarter of FY26, compared to a net profit of ₹ 77.5 crore in the same quarter last year. The infrastructure services company announced that it has bagged two operation and maintenance (O&M) contracts worth ₹ 551.35 crore, excluding taxes, duties, levies, cess, and GST. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
The Hindu
6 days ago
- Business
- The Hindu
Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.
Sun Pharmaceutical Industries Ltd has announced that it has entered into a settlement and license agreement with Incyte Corporation regarding litigation related to LEQSELVI (deuruxolitinib). 'Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation,' Sun Pharma said in a statement. As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent and certainother related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S. Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. 'Other specific terms of the settlement and license agreement are Confidential,' Sun Pharma said. After the settlement was reached, Sun Pharma has announced the launch of LEQSELVI 8 mg tablet in the United States for the treatment of severe alopecia areata. 'The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them,' said Richard Ascroft, CEO, Sun Pharma North America.
Mint
6 days ago
- Business
- Mint
Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
Sun Pharma on Monday announced it has settled a patent row with American biopharma company Incyte Corporation over its hair-loss drug, paving the way for its launch in the US. The Mumbai-based drugmaker, embroiled in the lawsuit since last year, launched the specialty drug in the world's largest pharmaceutical market on Monday. Leqselvi (oral deuruxolitinib) is indicated for treatment of adults with severe alopecia areata. Under the terms of settlement and licensing agreement, the two companies will seek a dismissal of the pending litigation in the United States District Court for the District of New Jersey, the company said in a release. Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. Incyte has also granted a limited, non-exclusive licence to Sun to US patents no. 9,662,335 and other related patents. This licence covers oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, the company said. In return, Sun will pay Incyte an upfront amount, as well as ongoing royalty payments until expiry of the patents. The company did not reveal other specific terms of the settlement. In April 2025, Sun Pharma received a favourable ruling from the US Court of Appeals for the Federal Circuit, which vacated a preliminary injunction on Leqselvi's launch, lifting restrictions on the launch. Sun received approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator's approval, Incyte Corporation filed a patent infringement lawsuit against Sun Pharma, alleging that Leqselvi infringed upon its existing patents, delaying the launch. In November 2024, the US District Court of New Jersey granted a preliminary injunction, halting Leqselvi's launch in the US until the lawsuit was resolved. Sun Pharma on Monday announced the launch of Leqselvi in the US, in a separate release. The drug will be available for prescription in 8mg tablets in the country. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," said Richard Ascroft, CEO, Sun Pharma North America, in the release. Leqselvi demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks. Leqselvi is expected to be a $200 million opportunity for Sun Pharma in 3-4 years after launch, according to brokerage Elara Capital. Sun Pharma's shares ended 0.58% higher at ₹ 1,681.70 apiece on NSE on Monday.
